A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01202188 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2144

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: indacaterol and glycopyrronium (QVA149)
DRUG: glycopyrronium (NVA237)
DRUG: indacaterol (QAB149)
DRUG: tiotropium
DRUG: placebo

Sponsor

Novartis Pharmaceuticals